Medicinal Products

Dáil Éireann Debate, Thursday - 19 March 2026

• Debates
• Find a debate
  • Dáil debates
  • Seanad debates
  • Committee debates
• Find a vote
  • Dáil votes
  • Seanad votes
  • Committee votes
• Parliamentary questions
  • Written questions
  • Oral questions
• Search tips
• Utterances having an adverse effect

Thursday, 19 March 2026

Questions (512)

John Clendennen

Question:

512. Deputy John Clendennen asked the Minister for Health for an update on the accessibility of the drug Givinostat (brand name Duvyzat) for the treatment of Duchenne muscular dystrophy, given the outcome of the NCPE assessment as of 3 March 2026; and if she will make a statement on the matter. [21310/26]

Written answers

Minister for Health

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

• Previous Answer
• Next Answer